Every 8-K that Citius Pharmaceuticals Inc. (CTXR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CTXR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTXR filings page.
Citius Pharmaceuticals, Inc. (CTXR) reports that Nasdaq has granted an extension through February 8, 2027 to regain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Listing Rule 5550(a)(2), the Bid Price Rule. The company will be deemed back in compliance if its common stock closes at or above $1.00 for at least ten consecutive business days before that deadline, after which Nasdaq would send written confirmation. If Citius does not regain compliance by the deadline, Nasdaq will issue a notice that its common stock is subject to delisting, and Citius may appeal to a Nasdaq hearings panel. CTXR shares continue to trade on the Nasdaq Capital Market, and the company states it is evaluating options to regain compliance but notes there is no assurance it will do so.
Citius Pharmaceuticals, Inc. reported fiscal third quarter 2026 results centered on the launch of LYMPHIR, its targeted immunotherapy commercialized through majority-owned Citius Oncology. Revenue was $1.49 million for the quarter and $7.11 million for the first nine months of fiscal 2026, all from LYMPHIR commercial sales.
Cash and cash equivalents were $17.0 million as of June 30, 2026. The company recorded a quarterly net loss attributable to common stockholders of $8.86 million and a nine‑month net loss of $38.3 million, with a nine‑month operating loss of $52.9 million and net cash used in operating activities of $23.0 million. Inventory totaled $22.6 million.
Management highlighted growing LYMPHIR adoption, including availability at 44 leading oncology centers and nationwide deployment of an expanded 29‑person commercial and medical affairs organization. Early‑stage data in combination with pembrolizumab and as a pre‑CAR‑T therapy showed encouraging response rates, and late‑stage programs Mino‑Lok and Halo‑Lido have completed pivotal and Phase 2b trials, respectively.
Citius Pharmaceuticals’ majority-owned subsidiary Citius Oncology provided an update on the commercial rollout of LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma. During the quarter ended June 30, 2026, new institutions ordering LYMPHIR increased 78% quarter over quarter, and vials ordered by institutions rose 31%. LYMPHIR is now available in 42 institutions, and the company is targeting formulary inclusion at 100 priority institutions by year-end, with more than 20 additional institutions anticipated during the current quarter. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, supported by near-universal payer coverage and an expanding wholesaler network, with revenue recognized when wholesale orders are placed and filled.
LYMPHIR is an IL2-receptor-directed cytotoxin approved in the U.S. in December 2025 for adults with relapsed or refractory Stage I–III CTCL after at least one prior systemic therapy. The therapy carries a boxed warning for capillary leak syndrome, which occurred in 27% of clinical trial patients, including a 0.8% fatal incidence, and is also associated with infusion-related reactions, hepatotoxicity, visual impairment, and embryo-fetal toxicity, requiring close monitoring and dose modifications based on severity.
Citius Pharmaceuticals, through its subsidiary Citius Oncology, reported early Phase 1 data on LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab in recurrent or refractory gynecologic cancers. In 21 efficacy-evaluable patients from a 25-patient study, 48% achieved clinical benefit, with a median progression-free survival of 20.5 months in this subgroup.
The heavily pre-treated population had a median of five prior therapies, and more than half had prior PD-1 or PD-L1 treatment. Investigators described durable responses and manageable tolerability, including activity in relapsed or refractory endometrial cancer. The study was investigator-initiated, open-label, and dose-escalation, and was not designed or powered to prove efficacy.
The company emphasized that LYMPHIR’s use in gynecologic malignancies remains investigational and outside its FDA-approved indication in cutaneous T-cell lymphoma. A Phase 2 expansion study is being planned, while ongoing translational work aims to identify biomarkers and refine future development strategies for this chemo-free immunomodulatory approach.
Citius Pharmaceuticals reported fiscal second quarter 2026 results, highlighted by initial LYMPHIR commercial traction and significantly higher operating losses. Revenue reached $1,667,298 for the quarter and $5,611,409 for the first half, compared with no revenue a year earlier, generating $4,493,323 in gross profit.
Operating expenses rose sharply, driving an operating loss of $32,194,786 and a net loss attributable to common stockholders of $29,451,925 for the first half. The company ended March 31, 2026 with $4,590,174 in cash and cash equivalents and total assets of $132,540,579. Management highlighted LYMPHIR’s launch progress, including strong payer coverage, and recent financings, including a $5 million registered direct offering and up to $36.5 million in Citius Oncology debt and equity commitments.
Citius Pharmaceuticals, Inc. entered into a Third Amendment to a promissory note with its majority-owned subsidiary, Citius Oncology, Inc., originally issued on August 16, 2024 in the principal amount of $3,800,111. The amendment ties repayment so that the entire unpaid principal is due 91 days after Citius Oncology’s senior debt is fully repaid and its related loan and security agreement is terminated. It removes prior maturity triggers linked to capital raises, new debt or equity issuances, or royalty-backed monetizations, and bars cash prepayments before the new maturity date. The amendment also adds a voluntary feature allowing the Company, with Citius Oncology’s approval, to convert some or all principal into common stock at a $0.90 per share conversion price.
Citius Pharmaceuticals, Inc., through its majority-owned subsidiary Citius Oncology, Inc., reports the first international shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe via a regional distribution partner. LYMPHIR will be provided to eligible patients through Named Patient Programs under local regulations, expanding access beyond the United States.
The filing also notes, by reference, a previously closed registered direct offering of common stock and a concurrent private placement of pre-funded, common, and placement agent warrants. LYMPHIR is an FDA-approved targeted immune therapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy and carries a boxed warning for capillary leak syndrome along with detailed safety and use information.
Citius Pharmaceuticals entered into a registered direct offering and concurrent private placement with institutional investors. The company sold 4,730,457 common shares and pre-funded warrants for 345,686 shares at $0.985 and $0.9849, respectively, plus unregistered warrants to purchase up to 5,076,143 shares at $0.86.
Gross proceeds were approximately $5.0 million, with expected net proceeds of about $4.5 million after fees. Citius plans to use the funds to support the commercialization of LYMPHIR™, advance development of its product candidates, and for general corporate purposes.
Citius Pharmaceuticals, Inc. reported results from its 2026 Annual Meeting of stockholders. Shareholders elected seven directors, including Leonard Mazur and Myron Holubiak, to one-year terms ending at the 2027 annual meeting or until successors are elected and qualified.
Stockholders also ratified Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2026, with 8,593,946 shares voting for, 855,866 against and 673,867 abstaining, and no broker non-votes reported on this item.
Citius Pharmaceuticals, through its majority-owned subsidiary Citius Oncology, reported early commercial and clinical progress for LYMPHIR, a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma. Management estimates the initial LYMPHIR market currently exceeds $400 million and is underserved by existing treatments.
The update highlights growing formulary adoption at leading oncology centers, broadening payer coverage, repeat orders, and adequate commercial supply. Citius Oncology is also expanding clinical development via academic collaborations, including studies in diffuse large B-cell lymphoma and solid tumors in combination with checkpoint inhibitor therapy.
Citius Pharmaceuticals, through its majority-owned subsidiary Citius Oncology, reported positive topline results from an investigator-initiated Phase 1 study of LYMPHIR™ (denileukin diftitox-cxdl) plus pembrolizumab in patients with recurrent or refractory gynecologic cancers.
The study in 25 evaluable patients showed no unexpected safety signals or serious immune-related adverse events at any dose level. Among 21 efficacy-evaluable patients, investigators observed a 24% objective response rate and a 48% clinical benefit rate, defined as complete or partial response or stable disease for at least six months.
The trial aimed to identify a recommended Phase 2 dose, and full safety and efficacy data are planned for presentation at an international cancer conference. LYMPHIR is already FDA‑approved and launched for relapsed or refractory Stage I–III cutaneous T‑cell lymphoma, where management estimates the initial market currently exceeds $400 million.
Citius Pharmaceuticals, through majority-owned subsidiary Citius Oncology, reported positive preliminary Phase 1 data for LYMPHIR when given before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. In 14 treated patients, investigators observed an 86% overall response rate, including 57% complete and 29% partial responses, with LYMPHIR described as well tolerated and without dose-limiting toxicities. The study was designed to enhance CAR-T effectiveness by depleting regulatory T-cells, and full results were presented at the 2026 Tandem Meetings. The attached exhibit also reiterates LYMPHIR’s existing FDA approval for cutaneous T-cell lymphoma and includes detailed safety warnings, highlighted by a boxed warning for capillary leak syndrome and other serious risks.
Citius Pharmaceuticals reported its first product revenue after the December 2025 launch of LYMPHIR through majority-owned Citius Oncology, recording $3.9 million in revenue for the fiscal first quarter ended December 31, 2025. Total revenue was $3,944,111, with a net loss attributable to common stockholders of $8,220,785, or $0.38 per share.
Cash and cash equivalents were $7,721,393 as of December 31, 2025, supported by $20,877,925 in net proceeds from common stock offerings during the quarter. Net cash used in operating activities was $13,008,822, and the company also paid $4,400,000 in license fees.
Citius received a Nasdaq notice that its common stock bid price has stayed below the $1.00 minimum for 30 consecutive business days. The company has 180 days, until August 10, 2026, to regain compliance, with the possibility of an additional 180-day period, and is evaluating options including a potential reverse stock split. The notice has no immediate effect on the Nasdaq Capital Market listing.
Citius Pharmaceuticals reported that it posted an updated Corporate Presentation on its website and furnished it as Exhibit 99.1 in an Item 7.01 Regulation FD disclosure. The company noted that this information is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference unless specifically referenced in a future filing.
Citius Pharmaceuticals (CTXR) completed a registered direct offering with an institutional investor, issuing 1,460,000 common shares at $1.51 and pre-funded warrants for up to 2,513,510 shares at $1.5099. The company also issued investor warrants to purchase up to 3,973,510 shares at an exercise price of $1.40, exercisable immediately for five years.
Gross proceeds were approximately $6.0 million, with expected net proceeds of about $5.5 million after fees. Citius plans to use the funds to support the commercial launch of LYMPHIR™, milestone and regulatory payments, development initiatives across its pipeline, and general corporate purposes. H.C. Wainwright acted as placement agent, earning a 7.0% cash fee plus expenses and received placement agent warrants for up to 278,146 shares at a $1.8875 exercise price.
The warrants include a 4.99% (or 9.99% if elected) Beneficial Ownership Limitation and allow cashless exercise if no effective resale registration is available. For 90 days after closing, Citius agreed not to issue additional equity, with an exception permitting “at the market” sales after 30 days at $2.15 or higher.
Citius Pharmaceuticals reported that it has issued a press release announcing its results of operations for the third quarter of fiscal 2025. The company states the press release is furnished as Exhibit 99.1 to the Form 8-K and is incorporated by reference into the report. The filing explains that the information in Item 2.02, including Exhibit 99.1, is furnished rather than filed for purposes of the Exchange Act and therefore is not subject to the same liabilities as a filed disclosure.
The Form 8-K lists the furnished exhibit and an interactive cover page document, and it is signed on behalf of the registrant by the chairman and chief executive officer. No financial line items, operating metrics, or forward-looking guidance appear within the 8-K text itself; readers must refer to Exhibit 99.1 for the underlying results.